长江生命科技(00775.HK) 公布，向纳斯达克上市公司Virios Therapeutics, Inc.(VIRI)出售创新止痛药附属-WEX 100%股本，总代价1亿美元，VIRI将透过发行21.13万股普通股；及2,108万优先股支付。完成发行普通股后，公司将持有VIRI股本约15.9%；优先股获行使后，公司于VIRI持股将增至90.7%。
同时，公司将向VIRI提供最多1,950万美元贷款，主要用于WEX进行有关旗舰产品Halneuron之营运及进行临床及研发资金。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.